Brainomix

Brainomix, a spinout from the University of Oxford, develops AI-powered software solutions for precision medicine, focusing on stroke and lung fibrosis. Their platform, Brainomix 360 Stroke, automates imaging biomarkers to improve diagnosis and treatment decisions, while they are also applying their AI expertise to predict the progression of lung fibrosis. They are an established European market leader with a NICE-endorsed technology that has benefited more than 1.5M patients.

Funding Round: Series C

Funding Amount: $18M

Date: 20-Mar-2025

Investors: Parkwalk Advisors, Boehringer Ingelheim Venture Fund (BIVF), Hostplus, IP Group Hostplus Innovation Fund, LifeSci Capital

Markets: Healthtech, AI

HQ: Oxford, England, United Kingdom

Founded: 2010

Website: http://www.brainomix.com/

LinkedIn: https://www.linkedin.com/company/brainomix/

Twitter: https://twitter.com/Brainomix

Instagram:

Facebook: https://www.facebook.com/brainomix